02/19/2021 | Press release | Archived content
OMER, Israel, Feb. 19, 2021 - Medigus Ltd. (NASDAQ:MDGS), a technology company engaged in advanced medical solutions and innovative technology, announced today the signing of a definitive agreement to form a joint venture, NewCo, for the development and commercialization of urban and logistics EV micro-mobility vehicles for 'last mile' delivery, and cargo. The signing of the definitive agreement relating to NewCo relates to the prior announcement in November 2020 regarding the execution of the non-binding memorandum of understanding with the EMuze founders.
The joint venture partners will include Mr. Amir Zaid, and Mr. Weijian Zhou, the founders of EMuze (a privately held company that designs and develops electric mobility micro vehicles), and Medigus via its wholly owned subsidiary Charging Robotics Ltd. Mr. Zaid is one of the leading designers in the global automotive industry and who was also part of the design of Italian vehicles manufacturer and other leading international car brands. He specializes in the micro mobility vehicles market and serves as the CEO of Emuze, an innovative urban transportation company aiming to provide safer, high-level personal transportation platforms that will help expand the use of micro mobility solutions.
Mr. Weijian Zhou is a manufacturer of high-end scooters, E-mobility and Skiing Machines. Mr. Zhou's operations are equipped with advanced machining and inspection facilities, an R&D center, and a Training Institute.
The joint venture's intended focus is to develop unique EVs that have the ability to last a full working day within a single charge, to suit a heavy-duty and rigid operation and be tailored mission-specific designs as well as Hop on -Hop off modes, off-road versions and a low cost of operation.
Medigus will be entitled to acquire up to 50.1% of the NewCo's share capital upon its incorporation, on a fully diluted basis, by investing up to US$1,350,000 upon NewCo meeting certain milestones as set in the agreement. Medigus will initially invest US$250,000 within 14 days of NewCo's incorporation, resulting in its ownership of 19.99% of NewCo's share capital. An additional US$400,000 will be invested based on predefined milestones which include the finalization of a design model within two months following the initial financing and formation of NewCo, the finalization of the development of an operational model of the 'PORTO' modular delivery vehicle and 3 sample 'PORTO' models within six months following the initial financing, the development of built-in tracking tool with a supporting software platform within eight months following the initial financing, and the execution of two material commercial agreements or long form engagements, for pilot projects, with at least two global shipping companies for product evaluation and purchase, within eight months following the initial financing. The second investment will result in Medigus holding 37.5% of NewCo's share capital on a fully diluted basis.
Within twelve months following the completion of the second financing, but in no event later than December 31, 2022, Medigus will be entitled to invest an additional amount of US$700,000, resulting in its ownership of 50.1% of NewCo's share capital on a fully diluted basis.
Medigus is traded on the Nasdaq Capital Market and the TASE (Tel Aviv Stock Exchange). To learn more about the company's advanced technology, please visit www.medigus.com.